Marker Therapeutics (NASDAQ:MRKR) Rating Lowered to “Hold” at Zacks Research

Marker Therapeutics (NASDAQ:MRKR) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

MRKR has been the subject of several other research reports. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. HC Wainwright initiated coverage on shares of Marker Therapeutics in a report on Monday, December 8th. They set a “buy” rating and a $10.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. Finally, UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Marker Therapeutics Stock Down 6.6%

Shares of MRKR opened at $1.71 on Monday. The company has a market cap of $28.51 million, a P/E ratio of -1.39 and a beta of 1.37. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.07. The firm’s 50 day moving average price is $1.33 and its 200 day moving average price is $1.23.

Marker Therapeutics (NASDAQ:MRKR) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.57. The business had revenue of $1.23 million during the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. Research analysts forecast that Marker Therapeutics will post -0.65 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

Several large investors have recently bought and sold shares of MRKR. Virtu Financial LLC purchased a new position in Marker Therapeutics during the 3rd quarter worth approximately $25,000. Two Sigma Investments LP acquired a new stake in shares of Marker Therapeutics in the third quarter valued at approximately $33,000. Finally, Jane Street Group LLC purchased a new position in shares of Marker Therapeutics during the second quarter worth approximately $33,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.